Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended		12 Months Ended
		Sep. 29, 2024	Oct. 01, 2023	Sep. 29, 2024	Oct. 01, 2023	Sep. 29, 2024
Restructuring Cost and Reserve [Line Items]
Restructuring charges	[1]	$ 217	$ 71	$ 1,331	$ 165
Biopharma [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		141		1,200
Realigning Our Cost Base Program [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost		2,300		2,300		$ 2,300
Restructuring cost incurred to date		1,800		1,800		1,800
Realigning Our Cost Base Program [Member] | Biopharma [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost		1,700		1,700		1,700
Restructuring cost incurred to date		1,400		1,400		1,400
Restructuring charges				(69)		1,300
Manufacturing Optimization Program [Member] | Biopharma [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred to date		1,300		1,300		1,300
Restructuring charges				1,300
Manufacturing Optimization Program - Phase One | Biopharma [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost		$ 1,700		$ 1,700		$ 1,700

[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $141 million for the three months ended September 29, 2024 (primarily including charges for our Realigning our Cost Base Program) and charges of $1.2 billion for the nine months ended September 29, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program and credits of $69 million for our Realigning our Cost Base Program). Amounts associated with our Biopharma segment for the three and nine months ended October 1, 2023 were not material.